Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen

References

• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsLancet200536594721687171715894097
   PubMed Web of Science ®Google Scholar
• DestaZWardBASoukhovaNVFlockhartDAComprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6J Pharmacol Exp Ther200431031062107515159443
   PubMed Web of Science ®Google Scholar
• HoskinsJMCareyLAMcLeodHLCYP2D6 and tamoxifen: DNA matters in breast cancerNat Rev Cancer20099857658619629072
   PubMed Web of Science ®Google Scholar
• GoetzMPSchaidDJWickerhamDLEvaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trialsClin Cancer Res201117216944695121880792
   PubMed Web of Science ®Google Scholar
• RaeJMDrurySHayesDFATAC trialistsCYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patientsJ Natl Cancer Inst2012104645246022395643
   PubMed Web of Science ®Google Scholar
• ReganMMLeyland-JonesBBouzykMBreast International Group (BIG) 1–98 Collaborative GroupCYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1–98 trialJ Natl Cancer Inst2012104644145122395644
   PubMed Web of Science ®Google Scholar
• BrooksJDTeraokaSNMaloneKEWECARE Study Collaborative GroupBernsteinJLFigueiredoJCVariants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE studyInt J Mol Epidemiol Genet201341354823565321
   PubMedGoogle Scholar
• ManiCGelboinHVParkSSPearceRParkinsonAKupferDMetabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylationDrug Metab Dispos19932146456568104124
   PubMed Web of Science ®Google Scholar
• IusufDTeunissenSFWagenaarERosingHBeijnenJHSchinkelAHP-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen, and restricts their brain penetrationJ Pharmacol Exp Ther2011337371071721378205
   PubMed Web of Science ®Google Scholar
• ChoiHKYangJWRohSHHanCYKangKWInduction of multidrug resistance associated protein 2 in tamoxifen-resistant breast cancer cellsEndocr Relat Cancer200714229330317639045
   PubMed Web of Science ®Google Scholar
• DaiDTangJRoseRIdentification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifosJ Pharmacol Exp Ther2001299382583111714865
   PubMed Web of Science ®Google Scholar
• HustertEHaberlMBurkOThe genetic determinants of the CYP3A5 polymorphismPharmacogenetics200111977377911740341
   PubMedGoogle Scholar
• HesselinkDAvan SchaikRHvan der HeidenIPGenetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimusClin Pharmacol Ther200374324525412966368
   PubMed Web of Science ®Google Scholar
• HaenischSZimmermannUDazertEInfuence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortexPharmacogenomics J200771566516788565
   PubMed Web of Science ®Google Scholar
• Kimchi-SarfatyCOhJMKimIWA “silent” polymorphism in the MDR1 gene changes substrate specificityScience2007315581152552817185560
   PubMed Web of Science ®Google Scholar
• ChoiJHAhnBMYiJMRP2 haplotypes confer differential susceptibility to toxic liver injuryPharmacogenet Genomics200717640341517502832
   PubMed Web of Science ®Google Scholar
• LaecheltSTurriniERuehmkorfASiegmundWCascorbiIHaenischSImpact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and functionPharmacogenomics J2011111253420351751
   PubMed Web of Science ®Google Scholar
• SchrothWHamannUFaschingPACYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratifcationClin Cancer Res201016174468447720515869
   PubMed Web of Science ®Google Scholar
• MadlenskyLNatarajanLTchuSTamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomesClin Pharmacol Ther201189571872521430657
   PubMed Web of Science ®Google Scholar
• XuYSunYYa oLAssociation between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatmentAnn Oncol20081981423142918407954
   PubMed Web of Science ®Google Scholar
• KiyotaniKMushirodaTImamuraCKSignificant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patientsJ Clin Oncol20102881287129320124171
   PubMed Web of Science ®Google Scholar
• ParkHSChoiJYLeeMJAssociation between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatmentJ Korean Med Sci20112681007101321860550
   PubMed Web of Science ®Google Scholar
• ToyamaTYamashitaHSugiuraHKondoNIwaseHFujiiYNo association between CYP2D6*10 genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatmentJpn J Clin Oncol2009391065165619596663
   PubMed Web of Science ®Google Scholar
• SukasemCSirachainanEChamnanphonMImpact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: a microarray-based study in ThailandAsian Pac J Cancer Prev20121394549455323167378
   PubMedGoogle Scholar
• ChamnanphonMPechatananKSirachainanEAssociation of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifenPharmgenomics Pers Med20136374823776391
   PubMedGoogle Scholar
• OkishiroMTaguchiTJin KimSShimazuKTamakiYNoguchiSGenetic polymorphisms of CYP2D6*10 and CYP2C19*2,*3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifenCancer2009115595296119156902
   PubMed Web of Science ®Google Scholar
• SchrothWAntoniadouLFritzPBreast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypesJ Clin Oncol200725335187519318024866
   PubMed Web of Science ®Google Scholar
• ZhouQYuXShuCAnalysis of CYP3A4 genetic polymorphisms in Han ChineseJ Hum Genet201156641542221412247
   PubMed Web of Science ®Google Scholar
• SupanyaDTassaneeyakulWSirivongsDPrevalence of CYP3A5 polymorphism in a Thai populationThai Journal of Pharmacology20093119597
   Google Scholar
• LimJSLChenXASinghOImpact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharma-cokinetics in Asian breast cancer patientsBr J Clin Pharmacol201171573775021480951
   PubMed Web of Science ®Google Scholar
• JinYDestaZStearnsVCYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatmentJ Natl Cancer Inst2005971303915632378
   PubMed Web of Science ®Google Scholar
• MurdterTESchrothWBacchus-GerybadzeLGerman Tamoxifen and AI Clinicians GroupEichelbaumMSchwabMBrauchHActivity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasmaClin Pharmacol Ther201189570871721451508
   PubMed Web of Science ®Google Scholar
• GoetzMRaeJSumanVPharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashesJ Clin Oncol200523369312931816361630
   PubMed Web of Science ®Google Scholar
• TuckerANTkaczukKALewisLMTomicDLimCKFlawsJAPolymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patientsCancer Lett20052171617215596297
   PubMed Web of Science ®Google Scholar
• GjerdeJGeislerJLundgrenSAssociations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancerBMC Cancer201010131320565970
   PubMed Web of Science ®Google Scholar
• MugunduGMSallansLGuoYShaughnessyEADesaiPBAssessment of the impact of CYP3A polymorphisms on the formation of α-hydroxytamoxifen and N-desmethyltamoxifen in human liver microsomesDrug Metab Dispos201240238939622096084
   PubMed Web of Science ®Google Scholar
• RooneyPHTelferCMcFadyenMCMelvinWTMurrayGIThe role of cytochrome P450 in cytotoxic bioactivation: future therapeutic directionsCurr Cancer Drug Targets20044325726515134533
   PubMed Web of Science ®Google Scholar
• MurrayGIPatimallaSStewartKNMillerIDHeysSDProfiling the expression of cytochrome P450 in breast cancerHistopathology201057220221120716162
   PubMed Web of Science ®Google Scholar
• BaldisseraVDde MattosAACoralGPEvaluation of the C3435T polymorphism in the MDR1 gene in patients with hepatocellular carcinomaAnn Hepatol201211689990623109454
   PubMed Web of Science ®Google Scholar
• KafkaASauerGJaegerCPolymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancerInt J Oncol20032251117112112684679
   PubMed Web of Science ®Google Scholar
• ChangHRhaSYJeungH-CAssociation of the ABCB1 gene polymorphisms 2677G.T/A and 3435C.T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patientsAnn Oncol200920227227718836089
   PubMed Web of Science ®Google Scholar
• IllmerTSchulerUSThiedeCMDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patientsCancer Res200262174955496212208746
   PubMed Web of Science ®Google Scholar